Joyce Antal
Clinical Development · Senior Director, Clinical Development
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joyce Antal as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:15 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06346067 · A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)Erasca, Inc. · active not recruiting · Advanced or Metastatic NRAS-mutant Melanoma · study director
- Ph1NCT05907304 · A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X MutationsErasca, Inc. · active not recruiting · Advanced or Metastatic Solid Tumors · study director
- Ph1/Ph2NCT05039177 · A Study of ERAS-007 in Patients With Advanced Gastrointestinal MalignanciesErasca, Inc. · completed · Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma · study director
- Ph1NCT04959981 · A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLCErasca, Inc. · completed · Advanced Non-squamous Non-small-cell Lung Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:15 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.JAMA Oncol · 2017726 citationsRCR 22.6
- 146 citationsRCR 4.3
- Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.Lancet Oncol · 201998 citationsRCR 3.2
- Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.J Thorac Oncol · 201986 citationsRCR 2.7
- 84 citationsRCR 4.2
- A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.Invest New Drugs · 201847 citationsRCR 1.5
- Experiences with L-deprenyl in Parkinsonism.J Neural Transm · 197838 citationsRCR 1.7
- Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.Arch Pathol Lab Med · 201930 citationsRCR 1.0
- Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects.J Clin Oncol · 199428 citationsRCR 0.7
- Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.Invest New Drugs · 20126 citationsRCR 0.3